Interferon γ-Induced Protein10 Kinetics in Treatment-Naive Versus Treatment-Experienced Patients Receiving Interferon-Free Therapy for Hepatitis C Virus Infection: Implications for the Innate Immune Response

被引：20

作者：

Lin, Jennifer C. ^{[1
]}

Habersetzer, Francois ^{[7
,8
,9
]}

Rodriguez-Torres, Maribel ^{[6
]}

Afdhal, Nezam ^{[3
]}

Lawitz, Eric J. ^{[4
]}

Paulson, Matthew S. ^{[2
]}

Zhu, Yanni ^{[2
]}

Subramanian, Gangadharan Mani ^{[2
]}

McHutchison, John G. ^{[2
]}

Sulkowski, Mark ^{[5
]}

Wyles, David L. ^{[1
]}

Schooley, Robert T. ^{[1
]}

机构：

[1] Univ Calif San Diego, La Jolla, CA 92093 USA

[2] Gilead Sci, Foster City, CA USA

[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[4] Alamo Med Res, San Antonio, TX USA

[5] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[6] Fdn Invest Diego, San Juan, PR USA

[7] Hop Univ Strasbourg, Strasbourg, France

[8] INSERM 1110, Strasbourg, France

[9] Univ Strasbourg, Strasbourg, France

来源：

JOURNAL OF INFECTIOUS DISEASES | 2014年 / 210卷 / 12期

基金：

美国国家卫生研究院;

关键词：

IP-10; hepatitis C; direct-acting antiviral therapy; innate immunity; INDUCIBLE PROTEIN-10; INFLAMMATION; RIBAVIRIN; CORRELATE; FIBROSIS; PREDICTS;

D O I：

10.1093/infdis/jiu325

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We measured interferon gamma-induced protein 10 (IP-10) levels in 428 patients at baseline, week 1, and week 2 of all-oral treatment for hepatitis C virus (HCV) infection. An increased baseline IP-10 level was associated with a T allele in the IL28B gene, an increased alanine aminotransferase level in treatment-naive but not experienced patients, and an increased body mass index. At week 1, the mean decline in plasma IP-10 levels was the same in treatment-naive and treatment-experienced patients (-49%), whereas during week 2 the mean decline in IP-10 levels in treatment-naive patients (-14%) was significantly larger than in treatment-experienced patients (-2%; P =.0176). IP-10 thus may be a surrogate marker of the rate of intracellular viral replication complex decay.

引用

页码：1881 / 1885

页数：5

共 50 条

[41] Randomized Trial of Interferon- and Ribavirin-Free Ombitasvir/Paritaprevir/Ritonavir in Treatment-Experienced Hepatitis C Virus-Infected Patients
Chayama, Kazuaki
Notsumata, Kazuo
Kurosaki, Masayuki
Sato, Ken
Rodrigues, Lino, Jr.
Setze, Carolyn
Badri, Prajakta
Pilot-Matias, Tami
Vilchez, Regis A.
Kumada, Hiromitsu
HEPATOLOGY, 2015, 61 (05) : 1523 - 1532
[42] Long-Term Clinical Value of Telaprevir for Treatment of Treatment-NaiVE and Treatment-Experienced Patients With Hepatitis C Virus (HCV) Infection: Projections Using Decision-Analytic Modeling
Brogan, Anita J.
Miller, Jeffrey D.
Talbird, Sandra E.
Thompson, James R.
Deniz, Baris
GASTROENTEROLOGY, 2011, 140 (05) : S947 - S947
[43] Pegylated interferon α-2a versus standard interferon α-2a for treatment-naive dialysis patients with chronic hepatitis C:: a randomised study
Liu, C-H
Liang, C-C
Lin, J-W
Chen, S-I
Tsai, H-B
Chang, C-S
Hung, P-H
Kao, J-H
Liu, C-J
Lai, M-Y
Chen, J-H
Chen, P-J
Kao, J-H
Chen, D-S
GUT, 2008, 57 (04) : 525 - 530
[44] Randomised trial of two different daily doses of interferon-α versus classical therapy in treatment-naive patients with chronic hepatitis C
Montalto, G
Tripi, S
Vuturo, O
Di Gaetano, G
Soresi, M
Spadaro, A
Aiello, A
Russello, M
Benigno, R
Siciliano, R
CLINICAL DRUG INVESTIGATION, 2002, 22 (09) : 623 - 631
[45] CLINICAL UTILITY OF HEPATITIS C VIRUS CORE ANTIGEN TESTING IN THE MONITORING OF TREATMENT NAIVE NON-CIRRHOTIC PATIENTS RECEIVING AN ALL-ORAL, INTERFERON-FREE REGIMIEN
Cloherty, G.
Cheng, K.
Chevaliez, S.
Wedemeyer, H.
Sarrazin, C.
Feld, J.
Maasoumy, B.
Herman, C.
Hackett, J., Jr.
Dawson, G.
Pawlotsky, J. M.
JOURNAL OF HEPATOLOGY, 2015, 62 : S617 - S617
[46] Bayesian network meta-analysis to evaluate interferon-free treatments in naive patients with genotype 1 hepatitis C virus infection
Trippoli, Sabrina
Fadda, Valeria
Maratea, Dario
Messori, Andrea
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 27 (08) : 983 - 984
[47] Efficacy and safety of ledipasvir/sofosbuvir in treatment-naive and-experienced patients with hepatitis C virus genotype 6 infection
Thong, Vo D.
HEPATOLOGY, 2017, 66 : 604A - 605A
[48] High dose induction therapy with consensus interferon followed by combination therapy with ribavirin for treatment-naive hepatitis C patients.
Kaiser, S
Kreysel, C
Hass, H
Gregor, M
HEPATOLOGY, 2001, 34 (04) : 581A - 581A
[49] Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens
Stepanova, Maria
Thompson, Alexander
Doyle, Joseph
Younossi, Issah
de Avila, Leyla
Younossi, Zobair M.
JOURNAL OF INFECTIOUS DISEASES, 2018, 217 (07): : 1033 - 1043
[50] Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis
Meissner, E. G.
Kohli, A.
Virtaneva, K.
Sturdevant, D.
Martens, C.
Porcella, S. F.
McHutchison, J. G.
Masur, H.
Kottilil, S.
JOURNAL OF VIRAL HEPATITIS, 2016, 23 (07) : 496 - 505

← 1 2 3 4 5 →